Reminder: Urologist Call on NMIBC & UTUC Landscape and Expectations for TYRA's Dabogratinib

Research evidence excerpt

Reminder: Urologist Call on NMIBC & UTUC Landscape and Expectations for TYRA's Dabogratinib

Guest Speaker

Dr. Pooya Banapour, MD, FACS - Urologic Oncologist and Surgeon at UNIO Health Partners

Barclays Host

Ellie Merle, CFA - US Biotechnology Analyst

Event Description

We're hosting a call with a urologist to discuss the diagnosis and evolving treatment

landscape for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) and low-

grade upper tract urothelial carcinoma (LG UTUC). We'll discuss TYRA's FGFR3-selective

inhibitor dabogratinib and the physician's expectations into TYRA's initial Ph2 data in IR

NMIBC expected in August.

LG UTUC & IR NMIBC background: Info on the diseases, current standard of care, and

physician's opinion on unmet need.

Biological rationale for FGFR3 inhibition in these indications: FGFR3 contribution to

disease pathology and rationale behind targeting FGFR3 in these scenarios.

Outlook for FGFR3 testing: Process and bottlenecks related to FGFR3 testing and

physician outlook for future testing.

Thoughts on dabogratinib and initial PoC data: Physician's view on dabogratinib as a

molecule and thoughts on initial Ph1 data in mUC.

LG UTUC and IR NMIBC landscape in development: Physician's view on what's approved

and the landscape in development for these indications.

Expectations for August IR NMIBC data: Physician's perspective on what to look for in

the dabogratinib initial Ph2 data.

Relevant Research

Tyra Biosciences: Mgmt dinner takeaways: What is the bar

for an oral in IR NMIBC? »

Tyra Biosciences: 1Q Take: NMIBC data in August, Achon

in 4Q – A major year ahead, we’re bullish »

Tyra Biosciences Inc: Urologist call takeaways: KOL

excited about TYRA's dabogratinib »

U.S. Small & Mid Cap Biotechnology: Transcript: Pediatric